Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | HRH2 | P25021 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14980281 | 0.98 | HTR1A (0.51) | HTR1ASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL18353898 | 0.98 | HTR1A (0.51) | HTR1ASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL18024036 | 0.92 | HTR1A (0.46) | HTR1ASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL4905012 | 0.91 | HTR1A (0.54) | HTR1ASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL8966405 | 0.91 | — | — | |
| SCHEMBL20231213 | 0.90 | ALDH1A1 (0.46) | HTR1ASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL31305372 | 0.89 | MEN1 (0.55) | HTR1ASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL31305373 | 0.89 | MEN1 (0.55) | HTR1ASMN1; SMN2KDM4EALDH1A1TSHR | |
| SCHEMBL2512123 | 0.89 | ALDH1A1 (0.55) | KDM4EALDH1A1DRD3USP2MEN1 | |
| SCHEMBL4381609 | 0.88 | ALDH1A1 (0.45) | HTR1ASMN1; SMN2KDM4EALDH1A1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107083-A2 | SHELF-STABLE LOXSH CATALYST SOLUTION COMPOSITIONS COMPRISING SOLUBLE HIGH HYDRIDE CONCENTRATIONS AND THE PROCESSES FOR PREPARING THEM | ALBEMARLE CORPORATION (US) | 2026-05-21 | — | — | WO | claimed |
| US-20250179233-A1 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC COPOLYMERIZATION OF CONJUGATED DIENES AND LIQUID COPOLYMERS THEREOF | ALBEMARLE CORPORATION (US) | 2025-06-05 | — | — | US | claimed |
| EP-4486808-A2 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC COPOLYMERIZATION OF CONJUGATED DIENES AND LIQUID COPOLYMERS THEREOF | ALBEMARLE CORPORATION (US) | 2025-01-08 | — | — | EP | claimed |
| CN-119137172-A | Process and catalyst for hydrogen-mediated anionic copolymerization of conjugated dienes and liquid copolymers thereof | 雅宝公司 | 2024-12-13 | — | — | CN | claimed |
| US-20240034825-A1 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC POLYMERIZATION OF CONJUGATED DIENES AND LIQUID POLYMERS THEREOF | ALBEMARLE CORPORATION | 2024-02-01 | — | — | US | claimed |
| WO-2023168218-A2 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC COPOLYMERIZATION OF CONJUGATED DIENES AND LIQUID COPOLYMERS THEREOF | ALBEMARLE CORPORATION (US) | 2023-09-07 | — | — | WO | claimed |
| EP-4208485-A1 | PROCESS AND CATALYSTS FOR HYDROGEN MEDIATED ANIONIC POLYMERIZATION OF CONJUGATED DIENES AND LIQUID POLYMERS THEREOF | ALBEMARLE CORPORATION (US) | 2023-07-12 | — | — | EP | claimed |
| CN-116368159-A | Process and catalyst for hydrogen-mediated anionic polymerization of conjugated dienes and liquid polymers thereof | 雅宝公司 | 2023-06-30 | — | — | CN | claimed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | claimed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| WO-2003045943-A1 | QUINAZOLINE COMPOUNDS WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | claimed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | claimed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | claimed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | claimed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| WO-2002034744-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | WO | claimed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | claimed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | claimed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | HTR1A 831/4885SMN1; SMN2 3491/4885KDM4E 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.